Altre lingue Galecto, Inc.

Azioni

GLTO

US36322Q1076

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 09/07/2024			Variaz. 5gg	Var. 1 gen.
0,5056 ^USD	-0,47%		+9,56%	-29,78%

10/06	GALECTO, INC. : Oppenheimer ancora positivo	ZM
01/05	Galecto, Inc. annuncia che il primo paziente è stato arruolato in uno studio di Fase 2 avviato da uno sperimentatore su GB1211 in combinazione con Pembrolizumab	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	01/05
Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	01/05
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results	21/12
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis	21/12
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis	21/12
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11
GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)	23/10/23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial	23/10/23
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial	23/10/23
Galecto Announces Plans to Explore Strategic Alternatives	26/09/23
Galecto to Explore Strategic Options, to Reduce Workforce	26/09/23
Galecto, Inc. Announces Executive Changes, Effective October 1, 2023	26/09/23
Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount	26/09/23
Galecto Announces Plans to Explore Strategic Alternatives	26/09/23
Galecto to Present at Investor Conferences in September	31/08/23
Sector Update: Health Care Stocks Declining in Late Afternoon Trading	15/08/23
Sector Update: Health Care Stocks Easing Tuesday Afternoon	15/08/23
Top Midday Decliners	15/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Galecto, Inc.

Azioni

GLTO

US36322Q1076

Altre lingue

Filtri